Hepatitis B Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatitis B stocks.

Hepatitis B Stocks Recent News

Date Stock Title
Jun 3 ARWR Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
Jun 2 BMY Emerging and Chinese pharmas playing greater role in oncology drug development
Jun 1 BMY Bristol Myers lung cancer drug Krazati succeeds in late-stage trial
Jun 1 BMY KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
May 31 ARWR Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
May 31 BMY Bristol Myers Squibb’s Breyanzi gains FDA approval for lymphoma
May 30 BMY Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking
May 30 BMY Bristol Myers' Breyanzi gains additional indication for mantle cell lymphoma
May 30 BMY Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
May 29 BMY Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
May 29 BMY Bristol-Myers gets EU approval for Opdivo for bladder cancer
May 29 BMY BMS secures another EC approval for Opdivo combination
May 29 GOVX GeoVax to Present at BIO International Convention 2024
May 29 BMY BMS stakes $80m on Prothena’s neurodegenerative candidate
May 29 ABUS Arbutus to Participate in Jefferies Global Healthcare Conference
May 29 BMY Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
May 29 ARWR Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
May 28 DVAX Dynavax to Present at Upcoming Investor Conferences
May 28 BMY ASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries
May 28 ARWR Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
Hepatitis B

Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver. It can cause both acute and chronic infections. Many people have no symptoms during the initial infection. Some develop a rapid onset of sickness with vomiting, yellowish skin, tiredness, dark urine and abdominal pain. Often these symptoms last a few weeks and rarely does the initial infection result in death. It may take 30 to 180 days for symptoms to begin. In those who get infected around the time of birth 90% develop chronic hepatitis B while less than 10% of those infected after the age of five do. Most of those with chronic disease have no symptoms; however, cirrhosis and liver cancer may eventually develop. These complications result in the death of 15 to 25% of those with chronic disease.The virus is transmitted by exposure to infectious blood or body fluids. Infection around the time of birth or from contact with other people's blood during childhood is the most frequent method by which hepatitis B is acquired in areas where the disease is common. In areas where the disease is rare, intravenous drug use and sexual intercourse are the most frequent routes of infection. Other risk factors include working in healthcare, blood transfusions, dialysis, living with an infected person, travel in countries where the infection rate is high, and living in an institution. Tattooing and acupuncture led to a significant number of cases in the 1980s; however, this has become less common with improved sterility. The hepatitis B viruses cannot be spread by holding hands, sharing eating utensils, kissing, hugging, coughing, sneezing, or breastfeeding. The infection can be diagnosed 30 to 60 days after exposure. The diagnosis is usually confirmed by testing the blood for parts of the virus and for antibodies against the virus. It is one of five main hepatitis viruses: A, B, C, D, and E.The infection has been preventable by vaccination since 1982. Vaccination is recommended by the World Health Organization in the first day of life if possible. Two or three more doses are required at a later time for full effect. This vaccine works about 95% of the time. About 180 countries gave the vaccine as part of national programs as of 2006. It is also recommended that all blood be tested for hepatitis B before transfusion and condoms be used to prevent infection. During an initial infection, care is based on the symptoms that a person has. In those who develop chronic disease, antiviral medication such as tenofovir or interferon may be useful; however, these drugs are expensive. Liver transplantation is sometimes used for cirrhosis.About a third of the world population has been infected at one point in their lives, including 343 million who have chronic infections. Another 129 million new infections occurred in 2013. Over 750,000 people die of hepatitis B each year. About 300,000 of these are due to liver cancer. The disease is now only common in East Asia and sub-Saharan Africa where between 5 and 10% of adults are chronically infected. Rates in Europe and North America are less than 1%. It was originally known as "serum hepatitis". Research is looking to create foods that contain HBV vaccine. The disease may affect other great apes as well.

Browse All Tags